PE20100254A1 - Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona - Google Patents

Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona

Info

Publication number
PE20100254A1
PE20100254A1 PE2009000782A PE2009000782A PE20100254A1 PE 20100254 A1 PE20100254 A1 PE 20100254A1 PE 2009000782 A PE2009000782 A PE 2009000782A PE 2009000782 A PE2009000782 A PE 2009000782A PE 20100254 A1 PE20100254 A1 PE 20100254A1
Authority
PE
Peru
Prior art keywords
suspension formulation
methyl
dosage form
pharmaceutical dosage
capsule including
Prior art date
Application number
PE2009000782A
Other languages
English (en)
Inventor
Roman Messerschmid
Rudolf Binder
Werner Brox
Thomas Klaus Bock
Original Assignee
Boehringer Ingelheim Int
R P Scherer Gmbh And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, R P Scherer Gmbh And Co Kg filed Critical Boehringer Ingelheim Int
Publication of PE20100254A1 publication Critical patent/PE20100254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A UNA FORMULACION EN SUSPENSION DE 3-Z-[1-(4-(N-((4-METIL-PIPERAZIN-1-IL)-METIL)-N-METIL-AMINO)-ANILINO)-1-FENIL-METILEN]-6-METOXICARBONIL-2-INDOLINONA-MONOETANOSULFONATO, QUE COMPRENDE UN VEHICULO LIPIDICO TAL COMO MONOGLICERIDOS ACETILADOS, OLEATO DE ETILO, GLICEROL, ENTRE OTROS; UN AGENTE ESPESANTE TAL COMO POLIETILENGLICOL SEMI-SOLIDO, ENTRE OTROS; UN DESLIZANTE/SOLUBILIZANTE TAL COMO LECITINA. COMPRENDE ADEMAS MACROGOLES. SE REFIERE TAMBIEN A UN METODO DE PREPARACION PARA UNA CAPSULA BLANDA Y CAPSULAS UTILES EN LA ADMINISTRACION DE LOS DERIVADOS DE INDOLINONA
PE2009000782A 2008-06-06 2009-06-04 Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona PE20100254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157748 2008-06-06

Publications (1)

Publication Number Publication Date
PE20100254A1 true PE20100254A1 (es) 2010-04-21

Family

ID=40911908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000782A PE20100254A1 (es) 2008-06-06 2009-06-04 Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona

Country Status (35)

Country Link
US (4) US20110301177A1 (es)
EP (1) EP2299987B1 (es)
JP (2) JP5661031B2 (es)
KR (2) KR101725469B1 (es)
CN (2) CN105193720B (es)
AR (1) AR072059A1 (es)
AU (1) AU2009254548B2 (es)
BR (1) BRPI0913434B8 (es)
CA (1) CA2726267C (es)
CL (1) CL2010001279A1 (es)
CO (1) CO6280467A2 (es)
CY (1) CY1120533T1 (es)
DK (1) DK2299987T3 (es)
EA (1) EA029996B1 (es)
EC (1) ECSP10010660A (es)
ES (1) ES2669469T3 (es)
HR (1) HRP20180709T1 (es)
HU (1) HUE039187T2 (es)
IL (1) IL208954A (es)
LT (1) LT2299987T (es)
MA (1) MA32385B1 (es)
MX (2) MX2010013203A (es)
MY (1) MY158930A (es)
NO (1) NO2299987T3 (es)
NZ (1) NZ603162A (es)
PE (1) PE20100254A1 (es)
PL (1) PL2299987T3 (es)
PT (1) PT2299987T (es)
RS (1) RS57142B1 (es)
SI (1) SI2299987T1 (es)
TW (1) TW201002691A (es)
UA (1) UA104590C2 (es)
UY (1) UY31879A (es)
WO (1) WO2009147212A1 (es)
ZA (1) ZA201007636B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2299987T (lt) 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
DK2575784T3 (en) 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
BR112015006363A2 (pt) 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CN112156081A (zh) * 2015-03-13 2021-01-01 江苏豪森药业集团有限公司 含有吲哚满酮衍生物混悬液的药物制剂及其制备方法
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
WO2018080795A1 (en) * 2016-10-25 2018-05-03 Glykon Technologies Group, Llc Hydroxycitric acid compounds and capsule liquid delivery
CN108066343A (zh) * 2016-11-08 2018-05-25 瑞阳(苏州)生物科技有限公司 一种预防或治疗肾纤维化疾病的药物
WO2018108669A1 (en) 2016-12-12 2018-06-21 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
AU2018357775B2 (en) 2017-10-23 2024-02-15 Boehringer Ingelheim International Gmbh New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
WO2019106692A1 (en) * 2017-11-29 2019-06-06 Sun Pharmaceutical Industries Limited Oral suspension of nintedanib esylate
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
CN113301884A (zh) * 2018-09-13 2021-08-24 夫特弗制药私人有限公司 非水性化疗口服悬浮液
CN113164402A (zh) * 2018-10-15 2021-07-23 希普拉有限公司 药物制剂
CN112386580B (zh) * 2019-08-13 2022-07-08 齐鲁制药有限公司 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用
JP2023504415A (ja) 2019-12-04 2023-02-03 イドーシア ファーマシューティカルズ リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
WO2021198253A1 (en) 2020-04-01 2021-10-07 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN114404382B (zh) * 2022-01-24 2023-05-12 南京康川济医药科技有限公司 乙磺酸尼达尼布软胶囊及其制备方法
WO2023161668A1 (en) 2022-02-28 2023-08-31 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060293260A1 (en) * 2005-05-24 2006-12-28 Wyeth Useful high load concentrate compositions for control of ecto-and endo-parasites
EP1948180B1 (en) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
KR101760657B1 (ko) * 2008-06-06 2017-07-24 베링거 인겔하임 인터내셔날 게엠베하 약제학적 병용물
LT2299987T (lt) 2008-06-06 2018-05-25 Boehringer Ingelheim International Gmbh Farmacinės vaisto formos kapsulė, apimanti indolinono darinio suspensijos kompoziciją
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法

Also Published As

Publication number Publication date
ECSP10010660A (es) 2011-02-28
KR101725469B1 (ko) 2017-04-11
US20110301177A1 (en) 2011-12-08
PL2299987T3 (pl) 2018-08-31
LT2299987T (lt) 2018-05-25
JP5661031B2 (ja) 2015-01-28
CA2726267C (en) 2017-10-31
EP2299987A1 (en) 2011-03-30
TW201002691A (en) 2010-01-16
CN105193720A (zh) 2015-12-30
SI2299987T1 (en) 2018-06-29
CA2726267A1 (en) 2009-12-10
US9907756B2 (en) 2018-03-06
US20140004187A1 (en) 2014-01-02
US20160324791A1 (en) 2016-11-10
CL2010001279A1 (es) 2011-05-13
WO2009147212A1 (en) 2009-12-10
MY158930A (en) 2016-11-30
BRPI0913434B8 (pt) 2021-05-25
DK2299987T3 (en) 2018-05-22
UA104590C2 (ru) 2014-02-25
EA201001856A1 (ru) 2011-06-30
CN102056598A (zh) 2011-05-11
EA029996B1 (ru) 2018-06-29
CN102056598B (zh) 2017-09-19
KR20170020557A (ko) 2017-02-22
NO2299987T3 (es) 2018-07-21
AR072059A1 (es) 2010-08-04
JP2014208712A (ja) 2014-11-06
CY1120533T1 (el) 2019-07-10
BRPI0913434A2 (pt) 2015-12-01
AU2009254548B2 (en) 2015-10-01
IL208954A0 (en) 2011-01-31
UY31879A (es) 2010-01-29
MA32385B1 (fr) 2011-06-01
MX359229B (es) 2018-09-20
AU2009254548A1 (en) 2009-12-10
JP5905542B2 (ja) 2016-04-20
US20160022672A1 (en) 2016-01-28
ES2669469T3 (es) 2018-05-25
KR20110017872A (ko) 2011-02-22
ZA201007636B (en) 2011-08-31
HRP20180709T1 (hr) 2018-06-15
CN105193720B (zh) 2018-07-31
HUE039187T2 (hu) 2018-12-28
EP2299987B1 (en) 2018-02-21
JP2011522812A (ja) 2011-08-04
CO6280467A2 (es) 2011-05-20
RS57142B1 (sr) 2018-07-31
IL208954A (en) 2017-11-30
BRPI0913434B1 (pt) 2020-10-13
NZ603162A (en) 2014-05-30
MX2010013203A (es) 2011-02-25
PT2299987T (pt) 2018-05-21

Similar Documents

Publication Publication Date Title
PE20100254A1 (es) Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
AR092857A1 (es) Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
CO6341565A2 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
WO2010117873A3 (en) Progesterone solutions for increased bioavailability
CL2012002424A1 (es) Método para tratar artitris reumatoide que comprende administrar al paciente laquinimod y metotrexato por vía oral; composición farmacéutica que los comprende.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
CO6511272A2 (es) Compustos de pirazol como antahonistas de crth2
CU20110233A7 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
CR11065A (es) Administracion semanal de inhibidores de peptidasa de dipeptidilo
ECSP10010167A (es) Composiciones oftálmicas novedosas
CR9703A (es) Derivados de pirazolona
CO6612270A2 (es) Método para preparar una capsula dura enterica y capsula dura enterica preparada por el mismo
EA201290552A1 (ru) Способ производства фармацевтически активного вещества
AR089203A1 (es) Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina y metodo de tratamiento
MX2009012782A (es) Formulaciones para administracion oral de agentes terapeuticos y metodos relacionados.
PE20120781A1 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
UY31839A (es) Compuestos
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
UY35235A (es) Unidad sólida con alto contenido en fexofenadina y su procedimiento de preparación.
BR112015004091A2 (pt) formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase

Legal Events

Date Code Title Description
FC Refusal